On January 13, 2020 Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, reported that 11 new partner programs entered clinical development in 2019 (Press release, Adimab, JAN 13, 2020, View Source [SID1234553110]). This brings the total number of Adimab partner programs that have entered the clinic to 32. Partners initiating clinical trials in 2019 include Alector, Dragonfly Therapeutics, Hanmi Pharmaceutical, IASO Therapeutics, Innovent Biologics, Inc., Roche, Surface Oncology, and others.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is the second year in a row that we have seen 11 or more new programs enter the clinic and we don’t expect that trend to slow anytime soon. In particular, we have seen younger companies backed by leading venture capital firms show remarkable success in translating new biological insight into clinical programs. On average, these venture-backed partners have advanced two out of every three discovery programs towards the clinic – that’s an incredible success rate compared to the industry at large," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "People aren’t very good at pricing failure. We see many antibody discovery shops push their cheap alternatives, but too many of those programs fail for technical or developability reasons."
In 2019, Adimab partners exercised ten commercial licenses to advance programs into product development, bringing the total number of optioned programs to more than 60. Partners exercising commercial options in 2019 include Acceleron, Innovent Biologics, Inc., Scholar Rock, Surface Oncology, and others.
"While the majority of the programs in the clinic came from Adimab’s core antibody discovery platform, there are now several programs in the clinic that came from new applications of Adimab’s technology. Some programs are antibodies that originally came from other technologies that we subsequently engineered to enhance their properties, or simply ‘fixed’ to reduce developability liabilities. We are also seeing a growing number of bispecific and CAR programs entering the clinic, and we expect that trend to continue in the coming years," said Guy Van Meter, Chief Business Officer of Adimab.